Abstract
No AccessJournal of UrologyAdult Urology1 Oct 2016Editorial Comment Christian G. Stief Christian G. StiefChristian G. Stief More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.05.116AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Editorial Comment." The Journal of Urology, 196(4), pp. 1103–1104 References 1 : Role of active surveillance and focal therapy in low and intermediate risk prostate cancers. World J Urol2015; 33: 907. Google Scholar 2 Emberton M: TOOKAD (padeliporfin) vascular-targeted photodynamic therapy versus active surveillance in men with low risk prostate cancer. A randomized phase 3 clinical trial. Presented at annual meeting of European Association of Urology, Munich, Germany, March 13, 2016; abstract LBA02. Google Scholar © 2016 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 196Issue 4October 2016Page: 1103-1104 Advertisement Copyright & Permissions© 2016 by American Urological Association Education and Research, Inc.MetricsAuthor Information Christian G. Stief More articles by this author Expand All Advertisement PDF downloadLoading ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
